..."The Company notes that Transgene is expected to announce...

..."The Company notes that Transgene is expected to announce shortly that Novartis will exercise a licence for further development of TG4010."

I would be cautious in embracing this extract from today's Virax statement.

My research tells me that neither Virax, nor Transgene, - nor perhaps even Novartis - know whether Novartis will announce exercise of its option to develop
TG4010.

I understand that Novartis is currently studying more information following Transgene's release of preliminary results of its Phase 11B trial on January 8.

Novartis will be watching the response of European regulatory authorities.

Question: Do the stock markets fully understand the clinical, financial and strategic issues that Novartis is currently working through?